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Insporadicepithelial ovarian cancer (EOC),the inactivation of BRCA1throughvarious mechanisms is arelatively common event.
BRCA1 protein dysfunction results in the breakdown of various critical pathways in the cell, notably, the DNA damage response
and repair pathway. Tumors from patients with BRCA1 germline mutations have an increased sensitivity to DNA damaging
chemotherapeutic agents, such as cisplatin, due to defective DNA repair. Thus, inhibiting BRCA1 in sporadic EOC using novel
targeted therapies is an attractive strategy for the treatment of advanced or recurrent EOC. Several classes of small molecule
inhibitors that aﬀect BRCA1 have now been tested in preclinical and clinical studies suggesting that this is a rational therapeutic
approach.TheaimofthispaperistoprovideanunderstandingofhowBRCA1hasevolvedintoapromisingtargetforthetreatment
of sporadic disease and to outline the main potential small molecule inhibitors of BRCA1 in EOC.
1.Introduction
Up to 10% of epithelial ovarian cancers (EOCs) are caused
by germline mutations in the tumor suppressor genes, Breast
Cancer 1 (BRCA1) and BRCA2 [1, 2]. Carriers of these
mutations have a risk of developing ovarian cancer of 18%–
54% by age 70; rates signiﬁcantly are higher than those
of the general population [3]. The majority of sporadic
EOCs display BRCA1 dysfunction or reduced expression,
due to factors such as somatic mutations or promoter
hypermethylation [4–6]. The BRCA1 t u m o rs u p p r e s s o rg e n e
codes for a 220kD nuclear phosphoprotein which has been
shown to be involved in many cellular processes such as
cell cycle checkpoint control, DNA damage recognition
and repair, apoptosis, the ubiquitin-proteasome pathway,
and transcriptional regulation [7–10]. BRCA1 is located
downstream in the cascade of the DNA damage sensors
ATM and ATR and is phosphorylated by these kinases
upon their activation in response to genotoxic stressors
such as radiation and chemotherapeutic agents. Once in its
phosphorylated state, BRCA1 becomes part of a number of
diﬀerent complexes which relocate to areas of damaged DNA
and coordinate cell cycle checkpoints in order to execute
DNA repair.
Ovarian cancer patients with tumors known to harbor
a germline mutation in BRCA1 are believed to display a
better response to platinum-based therapies and improved
survival compared to patients without BRCA1-associated
disease [11]. BRCA1 deﬁciency is believed to result in
deregulationofthecarefullycoordinatedDNArepaircascade
and thereby renders tumor cells more vulnerable to DNA
damaging agents and genomic instability. While this may
appear to be a distinct disadvantage for these cells in
terms of tumorigenesis, this situation can be advantageous
and potentially exploitable in the context of enhancing
the response to DNA damaging chemotherapeutic drugs.
The majority of patients demonstrate an initial response
to debulking surgery along with the ﬁrst-line therapy
regimen of platinum and taxane-based agents. However,
the majority will recur and develop platinum-resistance. To
overcome platinum resistance, there is a signiﬁcant need to
develop novel therapeutic options that will either enhance
the eﬀectiveness of standard chemotherapeutics or target a
subset of patient tumors based on molecular markers. This2 Journal of Oncology
paper focuses on novel therapeutic drugs in sporadic EOC
that directly or indirectly target BRCA1 and its interrelated
pathways. A review of BRCA1 gene therapy is provided as
well as an overview of the preclinical and clinical studies
on the most relevant small molecular inhibitors, poly(ADP-
ribose) polymerase-1 (PARP), histone deacetylases (HDAC),
checkpoint kinases (CHKs), and proteasome inhibitors in
the context of how these agents alter the BRCA1 pathway
to enhance sensitivity to platinum-based chemotherapy.
Finally,thepotentialforclinicaluseofBRCA1asabiomarker
in EOC is reviewed.
2. Gene Therapy
The ﬁrst eﬀorts to target BRCA1 in EOC involved restoring
BRCA1 function via gene therapy [12]. In its normal state,
BRCA1 functions as a tumor suppressor gene, inhibiting
the aberrant proliferation of tumor cells. However, BRCA1
rarely displays normal expression and function in EOC [5].
Thus, a logical therapeutic option is to restore the tumor
suppressor function of BRCA1 in cancer cells in order to
suppress cell proliferation. In a cell culture model, a normal
splice variant of BRCA1 was overexpressed by a retroviral
vector resulting in decreased cell proliferation. The cell line
wasthenimplantedintoamousexenograftmodelandtumor
growth suppression was observed [12]. Preclinical ﬁndings
indicated that restoration of normal function of BRCA1,
in a disease where its loss has been shown to contribute
to both its development and progression, could have the
therapeutic potential to inhibit tumor growth. In the Phase
I trial, twelve patients with recurrent metastatic ovarian
cancer, who had been treated with standard surgery and
chemotherapy, received one to three cycles of intraperitoneal
injections of BRCA1 in a retroviral vector. Two-thirds of
patients demonstrated stable disease for 4–16 weeks and
one third showed reduction of tumor burden. Given the
absence of signiﬁcant toxicity, a Phase II trial in patients
with less advanced disease was performed [13]. This trial
demonstrated little to no vector stability as well as a
rapid development of a neutralizing antibody response,
which was not observed in the previous trial. Furthermore,
there was no evidence of clinical response. The authors
postulated that this stark diﬀerence in results was likely due
to diﬀerences in immunocompetence between the patient
groups in each trial, attributable to diﬀerences in factors
such as tumor burden, number of chemotherapy treatments,
and nutritional status. The same group went on to design
a second-generation retroviral vector containing BRCA1.I n
preclinical eﬃcacy studies in mouse xenograft models, this
new vector was found to be minimally immunogenic and
increased survival compared to both the control vector and
the ﬁrst generation vector used in the Phase II trial [14].
No clinical trials with this vector have been reported to
date.
Vector reconstitution, in an attempt to regain normal
function of BRCA1, has never proceeded to Phase III study.
Thus, attention has recently focused on taking advantage
of the inherent weakness of BRCA1-deﬁcient tumor cells,
namely, the inability to eﬀectively repair DNA damage.
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Figure 1: Targeting BRCA1 as a therapeutic strategy in the treat-
mentofEOC.BRCA1iscentraltotheDNAdamageresponsewhich
is initiated following insults such as platinum-based chemothera-
peutic agents. Various small molecule inhibitors may target BRCA1
directlyorindirectly,ultimatelyleadingtofailuretorepairdamaged
DNA and apoptosis.
3.PARPInhibitors
A novel therapeutic option which has been the closest
to widespread clinical use in the treatment of EOC is
PARP inhibitors (PARPi) [15]. The PARP family of enzymes
catalyzes the polymerization of poly ADP-ribose from a
nicotinamide adenine dinucleotide (NAD+) substrate. They
play a critical role in the repair of single-stranded DNA
breaks (SSBs) via the base excision repair (BER) pathway
and inhibition of PARP results in failure of SSB repair.
Unrepaired SSBs which encounter a DNA replication fork
result in double-strand breaks (DSBs). Normal cells are able
to repair DSBs via the homologous recombination (HR)
DNA repair pathway. However, cells with defective BRCA1
are unable to repair DSBs due to defective HR repair and
are forced to use the error-prone nonhomologous end-
joining (NHEJ) pathway. The ensuing genomic instability
ultimately results in cell death (Figure 1). This ability to
preferentially target BRCA1-defective cells and spare those
with normal function made PARPi an attractive option for
the treatment of ovarian and breast cancer patients with
BRCA1 germline mutations. It is noteworthy that preclinical
studies examining the eﬀect of PARP inhibitors on BRCA-
deﬁcient cancers have focused on breast cancer models.
The ﬁrst preclinical work to demonstrate susceptibility
to PARP inhibitor-induced cytotoxicity in BRCA-null cells
was published simultaneously by two diﬀerent groups in
2005 [16, 17]. Bryant et al. showed that BRCA2-null V-C8Journal of Oncology 3
cells were extremely sensitive to PARP1 inhibitors of varying
potency and that this was likely due to their inability to
execute eﬀective HR repair. Farmer et al. also demonstrated
similar ﬁndings in BRCA2−/− mouse embryonic stem (ES)
cells, as well as BRCA1−/− ES cells. Treatment of V-C8
and BRCA-null ES cells with PARP inhibitors resulted in
an increase in chromosomal instability, cell cycle arrest, and
apoptosis. The results of the in vitro studies were validated
in vivo by creating xenograft mouse models using the same
V-C8 and BRCA2-null ES cell lines. It was consistently found
that treatment of the mice with PARP inhibitors blocked the
growthofBRCA-null tumors but had no signiﬁcant eﬀect on
reconstituted BRCA control tumors.
PARPi have also been shown to enhance the cytotoxicity
of platinum-based agents in vitro and in vivo, irrespective of
BRCA1 status. One study looked at a PARP-1 inhibitor, 3-
aminobenzamide, and found increased cisplatin cytotoxicity
in CH1cisR cisplatin-resistant ovarian tumor cells [18]. A
novel 3-aminomethyl carbazole imide PARP-1 and PARP-2
inhibitor, CEP-6800, was combined with cisplatin to treat
Calu-6-NSCLC cells [19]. Combination treatment displayed
more DNA damage than cisplatin alone. Furthermore, when
Calu-6-NSCLC tumor cells were implanted into a nude
mouse model, there was a 35% reduction in tumor growth
with CEP-6800/cisplatin combination treatment compared
to single-agent cisplatin.
There are preclinical data evaluating the combination
of PARPi and platinum-based agents in both BRCA-mutant
and BRCA-deﬁcient breast cancer models. Donawho et al.
used a BRCA1-deleted and a BRCA2-mutated MX-1 breast
carcinoma xenograft mouse model to perform the in vivo
evaluation of the Abbott Cancer Research PARPi, ABT-
888. [20]. ABT-888 was shown to potentiate cisplatin and
carboplatin cytotoxicity by inducing a greater regression of
established tumors compared to modest tumor inhibition
by platinum chemotherapy alone. Two studies analyzed a
PARP-1 inhibitor by AstraZeneca (AZD2281) in BRCA-
deﬁcient models [21, 22]. In the study by Evers et al.,
AZD2281 displayed strong growth inhibition of BRCA2-
deﬁcient mouse mammary tumor cell lines compared to a
BRCA2-proﬁcient control tumor cell line [21]. Synergistic
cytotoxicity in combination with cisplatin in the same model
system was shown. Rottenberg and colleagues used the
genetically engineered BRCA1-deﬁcient breast cancer mouse
model to establish AZD2281’s eﬃcacy alone and in combi-
nation with platinum-based agents [22]. When mice were
treated with AZD2281 alone versus vehicle-treated controls,
inhibitedtumorgrowthandincreasedsurvivalwasobserved.
Subsequently, AZD2281 was combined with either cisplatin
or carboplatin. This combination signiﬁcantly prolonged
the recurrence-free and overall survival compared to either
platinum drug alone.
Asaresultofthesepromisingﬁndings,therearecurrently
several PARPi in various stages of clinical development for
use in patients with BRCA1/2-mutant breast and ovarian
cancers (Table 1). The AstraZeneca/KuDOS compound KU-
0059436 (AZD2281) was evaluated in BRCA1/2 germline
mutation positive breast, ovarian, and prostate cancers in a
phase I trial [23]. This study showed that AZD2281 had few
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Figure 2: HDAC inhibition induces DNA damage and disrupts
DNA repair. Inhibiting HDAC causes hyperacetylation of DNA
and chromatin remodeling leading to more relaxed and open
DNA. This conformational change renders DNA more accessible
to cytotoxic DNA-damaging agents causing both upregulation and
downregulation of genes in the DNA damage and repair cascade.
adverse eﬀects,inhibited PARPand hadantitumor activity in
BRCA1/2 mutation positive patients.
A large proportion of sporadic EOCs display BRCA1
dysfunction and may behave similarly to BRCA1 germline
mutation-related disease in terms of overall survival, sensi-
tivity to platinum drugs and defects in DNA damage repair.
Given these ﬁndings, it is rational to extrapolate the use of
PARPi for the treatment of patients with sporadic EOC. A
number of clinical trials are currently underway examining
the eﬀect of PARPi alone or in combination with platinum
agents in ovarian cancers irrespective of BRCA1/2 mutation
status (Table 2).
4.HDACInhibitors
Histone Deacetylase Inhibitors (HDACi) have recently gen-
erated interest as a potential therapeutic option in the
treatment of cancer, having demonstrated their ability to
inhibit the proliferation of cancer cell lines in vitro and
in vivo [31]. Histone deacetylases are enzymes involved in
the posttranslational regulation of chromatin structure [32].
Their role is to catalyze the removal of acetyl groups from
lysine residues in the core histones of chromatin, resulting in
a more compact and transcriptionally repressed chromatin
structure. The mechanism by which HDACi suppress the
growth of cancer cells might be due to their inhibition
of acetyl group removal, resulting in the hyperacetylation
of chromatin structure. This causes chromatin to become
more relaxed and open, making it more accessible to DNA-
damaging agents and changing the expression of genes in
the DNA damage recognition and repair cascade (Figure 2).
There are several classes of HDACi including hydroxamic
acid-derived compounds (e.g., Trichostatin A and SAHA),
short-chain fatty acids (e.g., Sodium butyrate and valproic
acid), benzamides, cyclic peptides, and thiolates.
HDACi may have a signiﬁcant eﬀect on the sensitivity
of EOC tumors to DNA-damaging agents. Zhang et al.
performedageneexpressionproﬁleonsquamouscarcinoma
cells and observed that most genes involved in cell cycle4 Journal of Oncology
Table 1: Completed clinical trials evaluating potential drug targets of BRCA1.
Drug class Compound Phase Study population
PARP inhibitors KU-0059436 (AZD2281) Phase I BRCA1/2 germline mutation in
advanced breast and EOC [23]
HDAC inhibitors SAHA (vorinostat) Phase II Recurrent EOC [24]
CHK inhibitors
UCN-01 (staurosporine
derivative) in combination with
topotecan
Phase I Advanced solid tumors,
including EOC [25]
UCN-01 in combination with
topotecan
Phase II Recurrent EOC [26]
Proteasome inhibitors
PS-341 (bortezomib) in
combination with carboplatin
Phase I Recurrent EOC [27]
PS-341 in combination with
carboplatin
Phase I Platinum/taxane resistant EOC
[28]
PS-341 Phase II Recurrent, platinum-sensitive
EOC [29]
PS-341 in combination with
paclitaxel
Phase I Advanced solid tumours,
including EOC [30]
Table 2: Ongoing clinical trials evaluating potential drug targets of BRCA1.
Drug class Compound Phase Clinical trial number Study population
PARP inhibitors
MK4827 Phase I NCT00749502 EOC
AG014699 Phase II NCT00664781 Advanced EOC
KU-0059436 (AZD2281) Phase I NCT00647062 EOC with or without
BRCA1 mutation
KU-0059436 (AZD2281) in
combination with doxorubicin
Phase II NCT00628251 BRCA1/2 mutation positive
EOC
ABT-888 in combination with
bevacizumab, carboplatin,
paclitaxel
Phase I NCT00989651 EOC
ABT-888 in combination with
temozolomide
Phase I NCT00526617 EOC
KU-0059436 (AZD2281) Phase II NCT00679783 EOC with or without
BRCA1 mutation
KU-0059436 (AZD2281) Phase II NCT00753545 Platinum sensitive serous
EOC
BSI-201 Phase II NCT00677079 Advanced EOC
ABT-888 in combination with
topotecan
Phase I/II NCT01012817 EOC
HDAC inhibitors
SAHA (vorinostat) in
combination with paclitaxel,
carboplatin
Phase I/II NCT00772798 EOC
SAHA (vorinostat) in
combination with carboplatin,
gemcitabine
Phase I/II NCT00910000 EOC
Hydralazine and magnesium
valproate
Phase III NCT00533299 Advanced EOC
CHK inhibitors UCN-01 in combination with
irinotecan
Phase I NCT00031681 Metastatic EOC
Proteasome inhibitors
PS-341(bortezomib) in
combination vandetanib
Phase I/II NCT00923247 EOC
PS-341 Phase II NCT00023712 Platinum-sensitive EOCJournal of Oncology 5
control, DNA replication, and DNA damage repair were
downregulated when treated with Trichostatin A (TSA) [33].
Our group has shown that the treatment of A2780s/cp
ovarian cancer cells with the TSA analogue, M344, causes the
downregulation of BRCA1 mRNA and protein levels [34].
We have also shown that M344 was able to increase the
sensitivity of A2780s/cp ovarian cancer cell lines to cisplatin
and carboplatin, but not to taxol. Strait and colleagues
showed that TSA alone induced apoptosis in cisplatin
resistant ovarian cancer cell lines OVCA-3 and SKOV-3 [35].
Another study looked at several diﬀerent HDACi and found
that they all enhanced the cytotoxicity of cisplatin, but not
to metabolic antagonists or microtubule-damaging agents,
in six human ovarian cancer cell lines of varying cisplatin
sensitivity [36]. R306465 and PXD101, hydroxamate-based
HDACi, have shown eﬃcacy in A2780 xenograft mouse
models [37, 38]. Oral administration of R306465 in immun-
odeﬁcient mice was well tolerated and antitumor activity
of 76%–87% was observed compared to vehicle controls.
PXD101 showed single-agent antitumor eﬀect in xenograft
micethatwasenhancedbythecombinationwithcarboplatin
treatment.
SAHA (vorinostat) has been approved for the treatment
of cutaneous T-cell lymphoma and subsequently, a number
of clinical trials are currently underway to evaluate the
toxicity and dose of HDACi in solid tumors, including
ovarian cancer (Tables 1 and 2). A phase II study of SAHA
in recurrent ovarian cancer found that the treatment was
well tolerated but had minimal activity as a single agent
[24]. There are phase I/II trials underway examining the
combination of taxol, carboplatin, and SAHA as well as
carboplatin, gemcitabine, and SAHA. A phase III trial is
recruiting advanced ovarian cancer patients for treatment
with magnesium valproate, an HDACi, in combination
with hydralazine, an antihypertension agent. Since current
trials have focused on all ovarian cancer patients with
advanced/recurrent disease, there may also be a future role
for targeting a speciﬁc subset of the patient population based
on tumor biomarkers.
5.CHK1/2Inhibitors
Following DNA damage, BRCA1 is involved in the control
of cell cycle checkpoints, which represents another potential
mechanism to target BRCA1 therapeutically. Two genes
involved in this aspect of the DNA damage cascade are
Checkpoint Kinase 1 and 2 (CHK1 and CHK2). CHK1 is
activated by ATR in response to stressors such as replication
stress, chemotherapeutic agents, and SSBs; whereas CHK2
is activated by ATM in response to ionizing radiation,
chemotherapeutics, or DSBs [39]. Activation of CHK1/2
leads to arrest of the cell cycle at diﬀerent phases depending
on the speciﬁc kinase activated, allowing for DNA repair
to occur. The functional BRCA1 protein has been shown
to be phosphorylated and activated by CHK2, resulting in
the activation of CHK1. The presence of phosphorylated
BRCA1 aﬀects the expression and localization of Cdc25C,
ad o w n s t r e a mt a r g e to fC H K 1[ 40]. Inhibitors of CHK1/2
abrogate normal cell cycle arrest induced by their activation,
thereby preventing the repair of DNA damage (Figure 3).
Altering the function of the checkpoint kinases may directly
or indirectly impact BRCA1 function and thus may be a
suitable target for therapy in EOC.
Husain et al. found that the CHK inhibitor UCN-01,
a staurosporine derivative, potentiated the cytotoxicity of
cisplatin in a panel of ovarian cancer cells, with a notable
increase in apoptosis [41]. Furthermore, the cytotoxic eﬀect
was more pronounced in p53-wildtype cells. A phase I
clinical trial of UCN-01 in combination with topotecan was
performed in patients with advanced solid tumors, includ-
ing a signiﬁcant proportion of EOC [25]. This treatment
combination demonstrated some eﬃcacy and overall was
well tolerated. However in the Phase II trial examining
the same treatment in patients with advanced recurrent
ovarian cancer, no signiﬁcant antitumor eﬀect was seen
[26]. The eﬃcacy of CHK inhibitors in the context of
BRCA1 expression levels in EOC has not been examined,
but warrants investigation due to the interaction between
CHK1/2 and BRCA1 in the DNA damage cascade.
6.Proteasome Inhibitors
BRCA1 is known to have a role in the ubiquitin-proteasome
proteolysis pathway, whereby damaged and misfolded pro-
teins are tagged with a polyubiquitin chain and targeted for
ATP-dependent degradation by the 26S proteasome [42].
BRCA1 contains a zinc ring ﬁnger domain in its amino-
terminal region which has E3 ubiquitin ligase activity and
aids in the transfer of ubiquitin to the target substrate.
Mutations in the RING ﬁnger domain of BRCA1 are thought
to predispose to the development of cancer because they
abrogate ubiquitin ligase activity [43]. It has been suggested
that this particular function of BRCA1 may be critical to the
DNA recognition and repair process. As such, inhibitors of
the ubiquitin-proteasome pathway may oﬀer an alternative
therapeuticoptioninEOC,asinhibitionofthispathwaymay
result in defective repair of DNA damage (Figure 3).
Proteasome inhibitors include compounds such as pep-
tide aldehydes, boronates, and epoxyketones as well as β-
actones,whichpreventthedegradationofubiquitinatedpro-
teins. Several groups have demonstrated that the treatment
of ovarian cancer cell lines with a proteasome inhibitor in
combination with cisplatin treatment increased the cytotoxi-
cityofplatinumdrugs,increasedDNAdamageandinhibited
repair. Mimnaugh et al. pretreated ovarian cancer cells with
either ALLnL or lactacystin proteosome inhibitors prior
to cisplatin treatment and observed an abrogation in the
expected increase in excision repair cross-complementation
group 1 (ERCC1) expression with cisplatin and more
eﬃcient apoptosis [44]. The same group also evaluated
the combination treatment of the proteasome inhibitor
lactacystin with cisplatin in cisplatin-resistant ovarian can-
cer cells [45]. They observed the suppression of ERCC1
expression and inhibition of DNA repair with resultant
enhanced cisplatin cytotoxicity. In addition, the proteasome
inhibitor ALLnL was used in combination with cisplatin
treatment in A2780s and A2780cp ovarian cancer cells, a
cisplatin sensitive/resistant pair, and OVCAR3 cells [46].6 Journal of Oncology
DNA damaging agent
Ubiquitin-proteasome
proteolysis pathway
Proteasome
inhibitor
DNA damage repair
Cell cycle
arrest
CHK1/2
inhibitor
CHK1
ATM/ATR
CHK2
BRCA1
P
P
Figure 3: CHK1/2 and proteasome inhibition cause defects in the DNA damage repair pathway. CHK1 and CHK2 function to arrest the
cell cycle when DNA has been damaged, thus allowing time to repair the DNA lesions. CHK inhibition leads to continued cell cycling in the
presence of damaged DNA and is thought to alter the function of the DNA repair pathway.
They again found that cisplatin sensitivity was increased
in all of the cell lines, along with an increase in DNA
damage and defect in repair. They also noted a signiﬁcant
increase in the accumulation of cisplatin in the cells and a
reduction in cisplatin eﬄux. Recent work by Jandial et al.
has shown that the reduction of cisplatin eﬄux in ovarian
cancer cotreated with the proteasome inhibitor, PS-341, is
due to the prevention of cisplatin-induced downregulation
of the copper transporter 1 (CTR1), a major transporter of
platinum drugs [47].
Based on the preclinical results, proteasome inhibitors,
namely, PS-341, have entered into clinical trials, including
studies in EOC. In a Phase I trial examining a combination
of carboplatin and PS-341 in recurrent EOC, an overall
response rate of 47% was observed, including two patients
demonstrating a complete clinical response, one of whom
had platinum resistant disease [27]. Another recent Phase I
trial evaluated PS-341 in combination with carboplatin in
ovarian cancer patients with recurrent and platinum/taxane-
resistant disease [28]. The drug combination was well
tolerated, with just under half of the patients demonstrating
stable disease. There are currently Phase II clinical trials
assessing PS-341 either as a single agent or in combination
with other therapies in ovarian cancer presently underway
(Tables 1 and 2)[ 29, 30]. The combination of proteasome
inhibitors to platinum chemotherapy taking account BRCA1
mutation status or expression levels is a potential area of
future study in EOC.
7. BRCA1 asa Biomarker in EOC
A range of preclinical studies using both in vitro and in vivo
models have supported the association of low BRCA1 mRNA
and protein expression with an enhanced sensitivity to
platinum agents [48, 49]. An ovarian cancer cell line SKOV3,
which expresses high levels of BRCA1, was the model used
to assess the role of BRCA1 in cisplatin sensitivity. Husain
et al. depleted BRCA1 levels by an antisense inhibition
approach to sensitize SKOV3 cells to cipslatin [48]. Zhou et
al. used a retrovirus-mediated siRNA interference approach
to show similar results [50]. Another group used both BG-1
and OVCAR5 ovarian cancer cell lines that were either
stably transfected with a BRCA1 antisense construct or
transiently transfected with a siRNA against BRCA1 [49].
The cells that displayed reduced BRCA1 expression were
more sensitive to platinum agents than their empty vector
and scrambled oligonucleotide controls. Using two diﬀerent
models to target the inactivation of Brca1 in mouse ovarian
surface epithelial cells, an increase in chemosensitivity and
an enhanced apoptotic response to cisplatin in the absence
of Brca1 in this tissue was reported, suggesting that this
phenomenon is also present in normal cells [51, 52]. Fur-
thermore, in the ID8 mouse EOC cell line, Brca1 expression
hasalsobeenshowntomediatesensitivitytoplatinumagents
[53].
EOC patients with germline mutations in the BRCA1
tumor suppressor gene have an improved initial response to
treatment with platinum-based chemotherapy regimens and
have an improved overall survival [54]. Several studies have
also shown a reduction in BRCA1 expression in sporadic
EOCs compared to normal ovarian tissue, as assessed by
methods such as immunohistochemistry (IHC), loss of
heterozygosity, mRNA levels, and hypermethylation of the
BRCA1 promoter [55]. Recent data also indicates that
BRCA1 levels may be predictive of response to treatment
and overall survival in sporadic EOC. In the largest studyJournal of Oncology 7
of 230 patients with sporadic EOC, Thrall et al. analyzed
BRCA1 protein expression by IHC and found that decreased
BRCA1 expression was protective for survival [56]. IHC was
performed on formalin-ﬁxed-paraﬃn-embedded (FFPE)
samples with the mouse monoclonal antibody speciﬁc to the
amino-terminal of the BRCA1 protein. The study was scored
basedonpreviouslypublishedmethodsusedinbreastcancer
[57],withascoreof0–4,basedonthenumberofcellsstained
in a ﬁeld of view. Several other groups have also assessed
BRCA1 protein levels via IHC in sporadic EOC in smaller
sample sizes, with reduced expression found in between 34%
and 90% of tumors [58–60] .T h es t u d i e sb yW a n ge ta l .a n d
Zheng et al. followed the same experimental conditions as
Thrall’s group in terms of using FFPE samples and the same
BRCA1 antibody epitope. Russell’s study performed IHC on
ﬂash frozen sections and they used six diﬀerent antibodies
ranging in epitope from the amino to the carboxy terminus.
With this rigorous approach, they were able to ﬁnd reduced
or absent BRCA1 protein expression in 90% of their cases.
However, it must be considered that such a wide range of
results may be attributed to variations in inclusion criteria
as well as the relatively subjective nature of IHC scoring.
The group of Quinn et al. was the ﬁrst to report that
decreased BRCA1 mRNA expression by quantitative RT-
PCR in tumors from patients with sporadic EOC who
received platinum-based chemotherapy was predictive of an
improved overall survival [49]. Our recent study substanti-
ates these results by showing that lower BRCA1 expression
predicts for longer overall survival, especially in patients
who were optimally debulked <2cm at the time of staging
laparotomy [34]. While RNA analysis is a more quantitative
approach,itnot onlyrequirestheavailability offrozen tissue,
but RNA extraction is a more time-consuming approach
than IHC on samples which are processed on a tissue
microarray.Furthermore,unlessthemRNAanalysishasbeen
done from microdissected samples, the tissue sample itself
may be a mixture of heterogeneous tissue including normal,
nonmalignant tissue.
A consistent ﬁnding in the few studies on human EOC
tumors is that BRCA1 mRNA and protein are frequently
expressed at low levels within cell nuclei relative to the
commonly used positive tissue control MCF7, a breast
cancer cell line. This may represent a potential challenge in
utilizing BRCA1 as a clinically useful predictive marker. Dis-
tinguishing “high” expressors from “low” expressors can be
particularly diﬃcult, especially at the protein level via IHC,
where the scoring method is usually qualitative. Quantitative
methods such as analysis of mRNA levels may provide more
accurate results and could facilitate diﬀerentiating between
true high and low expressors in a population where baseline
levels are low. Considerable success using this method has
been achieved in the use of BRCA1 as a predictive marker in
nonsmall cell lung cancer (NSCLC) [61].
8. Conclusion
The array of cellular processes in which BRCA1 plays an
integral role oﬀers several mechanisms by which its function
could be targeted for the treatment of EOC. All of these
options take advantage of the weakness that is central in
a BRCA1-deﬁcient cell, the inability to eﬀectively repair
damaged DNA. As a result, the therapies outlined in this
review oﬀer promise not just in BRCA1 mutation-associated
EOC, but to the large proportion of patients with sporadic
disease with tumors that display BRCA1 deﬁciency due to
epigenetic changes. Furthermore, as BRCA1 shows promise
as a prognostic and predictive marker in sporadic EOC,
patients identiﬁed as being high expressors could be treated
with agents that downregulate BRCA1, thus sensitizing them
to standard therapies. Further work, both in vitro and in
clinical trials, is needed to assess the correlation between
BRCA1 expression levels and response to these potential
targeted therapies.
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